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Mutations in LRRK2 are a common cause of genetic Parkinson’s disease (PD). LRRK2 is a
multi-domain Roco protein, harbouring kinase and GTPase activity. In analogy with a bacterial
homologue, LRRK2 was proposed to act as a GTPase activated by dimerization (GAD), while
recent reports suggest LRRK2 to exist under a monomeric and dimeric form in vivo. It is
however unknown how LRRK2 oligomerization is regulated. Here, we show that oligomer-
ization of a homologous bacterial Roco protein depends on the nucleotide load. The protein is
mainly dimeric in the nucleotide-free and GDP-bound states, while it forms monomers upon
GTP binding, leading to a monomer-dimer cycle during GTP hydrolysis. An analogue of a PD-
associated mutation stabilizes the dimer and decreases the GTPase activity. This work thus
provides insights into the conformational cycle of Roco proteins and suggests a link between
oligomerization and disease-associated mutations in LRRK2.
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Mutations in the gene encoding leucine-rich-repeat kinase2 (LRRK2) are the most common genetic cause ofParkinson’s disease (PD)1, 2. LRRK2 mutations account
for 5–6% of familial PD cases, and are identiﬁed as a risk factor
for sporadic forms of the disease3. LRRK2 is a large (2527 amino
acids) multi-domain protein, belonging to the Roco protein
family. This protein family is characterized by the presence of a
GTPase domain, called Roc (Ras of complex proteins), fused to a
COR domain (C-terminal of Roc)4, 5. In many cases this Roc-
COR module is preceded by a leucine-rich-repeat (LRR) domain
and followed by a protein kinase domain. In LRRK2 a number of
additional protein-protein interaction domains are present6, 7.
The pathogenic LRRK2 mutations mainly cluster in the catalytic
Roc-COR and kinase domains, and the most prevalent mutations
result in decreased GTPase activity and/or enhanced kinase
activity8–13. This coupled phenotype may point towards an
intramolecular regulatory mechanism between the Roc and
kinase domains, thus underscoring the central role of the Roc
GTPase cycle in PD pathology.
Signiﬁcant progress in our understanding of the structure and
mechanism of the Roc-COR module of LRRK2 comes from
studies with related Roco proteins from prokaryotes and lower
eukaryotes7, 14–16. Most importantly, the model that LRRK2
functions as a GAD (G protein activated by nucleotide-dependent
dimerization) is heavily based on the crystal structure of the
dimeric Roc-COR module of the Roco protein from Chlorobium
tepidum14, 17, 18. This model implies that the COR domain acts as
a permanent dimerization device and that the stimulation of
GTPase activity depends on reciprocal complementation of two
Roc active sites7, 14, 15, 17, 19. Similar to the prokaryotic Roco
proteins, various studies report that LRRK2 can also form dimers
through its Roc-COR domain in vitro15, 20–22, although some
other studies suggest that the protein is mainly monomeric23. A
number of recent results indicate that in vivo functional LRRK2
cycles between a predominantly monomeric kinase-inactive form
in the cytosol and a dimeric kinase-active form at the plasma
membrane24, 25. However, so far the mechanisms regulating these
changes in LRRK2 translocation and oligomerization are poorly
understood.
Here, we show that Roco proteins cycle between a monomeric
and dimeric form during GTP turnover. Using small angle X-ray
scattering (SAXS), multi-angle light scattering (MALS), native
mass spectrometry (MS), analytical ultracentrifugation (AUC)
and electron microscopy (EM), we demonstrate that the C. tepi-
dum Roco protein is mainly dimeric in the nucleotide-free and
GDP-bound states, while it is mainly monomeric when bound to
GTP. Moreover, using time resolved Förster resonance energy
transfer (FRET) and EM we show that the GTP-induced mono-
merization occurs on a catalytically relevant time scale and that
the monomer-dimer cycle occurs concomitant with GTP turn-
over. A mutation linked to PD decreases the GTPase activity by
interfering with the monomer-dimer equilibrium. Together these
results shed new light on a long-standing discussion regarding the
oligomeric state of Roco proteins, and propose a model for their
GTP hydrolysis mechanism.
Results
GppNHp binding induces monomerization of the Roc-COR
module. Like most prokaryotic Roco proteins, the Roco protein
from Chlorobium tepidum (CtRoco) consists of an N-terminal
LRR domain (a.a. 1–411), a central Roc-COR module (a.a.
412–946) and a C-terminal region of unknown structure and
function (a.a. 947–1102) (Supplementary Fig. 1)4, 14, 15. A crystal
structure of the Roc-COR domain construct of CtRoco (CtRoc-
COR) was solved, with the Roc GTPase domain in a nucleotide-
free state14. This structure shows the protein as a homodimer, for
which most of the contacts between the subunits are mediated via
COR domain residues. To investigate the inﬂuence of nucleotide
binding on the conformation of CtRoc-COR we set out to per-
form small angle X-ray scattering coupled to size-exclusion
chromatography (SEC-SAXS) experiments with the protein in
either the nucleotide-free state or saturated with GDP or the GTP
mimic 5′-guanylyl imidodiphosphate (GppNHp) (Supplementary
Fig. 2). The scattering proﬁle of the nucleotide-free protein is in
excellent agreement with the symmetrical CtRoc-COR dimer of
the crystal structure (pdb 3DPU, Gotthardt et al. 2008), and a
comparison of the experimental and theoretical scattering proﬁles
yields a χ2-value of 0.9 (Fig. 1a). Moreover, a good agreement is
found between the ab initio molecular envelope based on the
SAXS proﬁle and the CtRoc-COR crystal structure (Fig. 1b).
However, when CtRoc-COR is saturated with either GDP or
GppNHp conformational changes are taking place, as the
experimental scattering curves yield a worse ﬁt with the theore-
tical scattering curve based on the nucleotide-free crystal struc-
ture (translated in a χ2 = 1.6 and χ2= 6.0 for GDP- and
GppNHp-bound protein respectively). To obtain further
insights in the nature of these conformational changes we cal-
culated the estimated molecular masses based on the Porod
volumes. For both the nucleotide-free and the GDP-bound form,
a molecular mass around 120 kDa is found, which is in good
agreement with the expected molecular mass of the dimer (the-
oretical MMdimer= 130 kDa) (Fig. 1c). In the GppNHp-bound
state an average molecular mass of 90 kDa is found, in between
the values expected for a monomer and a dimer. This indicates a
monomer/dimer equilibrium with overlapping peaks in the
chromatogram at the concentration used in SEC-SAXS (50 µl of
an 8 mgml−1 protein solution injected on the column). Such a
shift in oligomerization is also translated in the pair-distance
distribution functions, where an overlay shows that the curves
overlap for the nucleotide-free and GDP loaded protein, while a
shift toward on average smaller distances is found for the
GppNHp-bound protein (Supplementary Fig. 2d).
Next, we performed multi-angle light scattering coupled to
size-exclusion chromatography (SEC-MALS) and sedimentation
velocity analytical ultracentrifugation (SV-AUC) experiments to
determine the molecular mass of CtRoc-COR in different
nucleotide states (Figs. 1c, d). For the SEC-MALS experiments,
10 µl of 8 mgml−1 protein solutions were injected on the SEC
column. For the nucleotide-free and GDP-bound forms a
molecular mass of 120 and 125 kDa is obtained respectively,
again corresponding to a dimer. For the GppNHp-loaded protein
SEC-MALS yielded a molecular mass of 78 kDa, just slightly
above the expected value of a monomer. The SV-AUC
experiments were performed at an even lower protein concentra-
tion (0.3 mgml−1, 4.6 µM) (Fig. 1c and Supplementary Fig. 3).
Again, for nucleotide-free and GDP-loaded CtRoc-COR mole-
cular masses of 121 and 115 kDa are obtained (sedimentation
coefﬁcients of 4.7 S and 4.8 S, respectively). In the presence of
GppNHp the monomer-dimer equilibrium is almost completely
shifted to the monomer, clearly seen as a shift in sedimentation
coefﬁcient from around 4.8 S (dimer) to 3.6 S (monomer),
corresponding to a molecular mass of 69 kDa.
Finally, to resolve monomeric and dimeric species we
performed native MS experiments (Fig. 1e). The mass spectrum
of nucleotide-free CtRoc-COR shows exclusive dimeric species
(MMexp= 130 kDa). Also with GDP dimeric species dominate,
while a very small amount of monomer appears (MMexp= 65
kDa). However, in agreement with our previous data, we observe a
clear shift toward the monomeric species in the presence of
GppNHp, resulting in an approximately 50:50 monomer/dimer
ratio under the conditions used in this experiment.
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In conclusion, all these experiments show that while the
CtRoc-COR is mainly a dimer in the nucleotide-free and GDP-
bound form, the GTP mimic GppNHp induces monomerization
in a concentration dependent manner.
GppNHp shifts the dimer-monomer equilibrium in CtRoco.
Considering the GppNHp-induced monomerization observed in
the CtRoc-COR construct, we next collected SAXS data for the
full length CtRoco protein, either in the absence of nucleotides or
bound to GDP or GppNHp (Supplementary Fig. 4). As there is,
thus far, no crystal structure available of the full length CtRoco
protein (nor of any other Roco protein), no ﬁtting of the SAXS
data on a theoretical curve could be performed. However, visual
inspection of the scattering curves clearly shows that conforma-
tional changes occur in both the CtRoco GppNHp- and GDP-
bound states compared to the nucleotide-free state (Fig. 2a and
Supplementary Fig. 4e). Docking of the CtRoc-COR crystal
structure into the ab initio envelope generated from the SAXS
data of the nucleotide-free CtRoco protein show additional fea-
tures at the N- and C-terminus of CtRoc-COR presumably cor-
responding to the LRR and C-terminal domains (Fig. 2b).
Molecular mass calculation from the Porod analysis of the
SAXS curves, from SEC-MALS and from SV-AUC (Figs. 2c, d
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Fig. 1 The Chlorobium tepidum Roc-COR domain monomerizes upon binding of a non-hydrolysable GTP analogue (GppNHp). a Pairwise-comparison using CRYSOL
of the theoretical scattering curve derived from the crystallographic dimer model of CtRoc-COR (PDB 3DPU, grey line) with the experimental scattering curves of
CtRoc-COR in the absence of nucleotides (black dots) or in the presence of GDP (green dots) or GppNHp (red dots). b Superposition of the crystallographic CtRoc-
COR dimer model (Roc in red and COR in blue) on the ab initio SAXS envelope, constructed starting from the scattering curve of CtRoc-COR in the absence of
nucleotides. cOverview of the molecular masses obtained via SAXS (based on Porod volume/1.7), SEC-MALS and SV-AUC for CtRoc-COR in different nucleotide-
bound states. The theoretical molecular mass of the monomer is given in between brackets. (NF= nucleotide-free) d SEC-MALS data for CtRoc-COR in the
absence (black) or presence of nucleotides GDP (green) or GppNHp (red). e Native mass spectra of CtRoc-COR for the three different nucleotide states: nucleotide-
free (NF), GDP-bound and GppNHp-bound. Peaks corresponding to dimeric and monomeric species are labeled with two circles and one circle, respectively
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and Supplementary Fig. 5), yields values between 240 and 290
kDa for the nucleotide-free and GDP-bound forms, close to the
theoretical value expected for a dimer (theoretical MMdimer=
254.2 kDa). In the presence of GppNHp, SEC-SAXS (50 µl of an
8 mgml−1 protein solution injected on a column) gives a
molecular mass of 209 kDa and SEC-MALS (10 µl of an 8 mg
ml−1 protein solution injected on a column) a molecular mass of
173 kDa, while SV-AUC (protein at 0.6 mgml−1, 4.5 µM) gives a
broader distribution with a molecular mass at the peak of 158
kDa (sedimentation coefﬁcient of 4.9 S) (Supplementary Fig. 5).
As for CtRoc-COR this indicates that GppNHp induces
monomerization, with the protein existing in a concentration
dependent monomer/dimer equilibrium. Finally, native-MS
spectra of CtRoco show mainly dimeric species (MMexp= 256
kDa) with a very small amount of monomers (MMexp= 128 kDa)
for nucleotide-free and GDP-loaded protein and a 50:50
monomer-dimer ratio for the GppNHp loaded protein (Fig. 2e).
It might seem remarkable at ﬁrst sight that despite the
difference in molecular mass the nucleotide-free, GppNHp- and
GDP-bound CtRoco proteins elute at approximately the same
volume in SEC (Fig. 2d). Correspondingly, Guinier analysis of the
SAXS data shows that the radius of gyration (Rg) even increases
upon going from the nucleotide-free state, over the GDP-bound
state to the GppNHp-bound state (Supplementary Fig. 4). This
could be explained by a conformational change occurring in the
CtRoco subunits upon monomerization or upon nucleotide
binding. Indeed, as is the case for the CtRoc-COR construct,
the SAXS pair-distance distribution function of CtRoco shows a
shift toward shorter average inter-atom distances in the presence
of GppNHp compared to GDP or nucleotide-free states,
indicative of monomerization (Supplementary Fig. 4d). However,
the curve of the GppNHp-bound CtRoco protein also shows a
tailing toward longer maximal distances. This strongly suggests
the occurrence of a GppNHp-bound monomer that is more
elongated than the corresponding subunits in the nucleotide-free
dimer. Also in the GDP-bound state tailing of the pair-distance
distribution function is observed indicating that already some
conformational changes occur in the dimeric nucleotide-bound
protein. These conformational changes also explain why the
observed monomer/dimer equilibrium would probably be missed
when assessed only with size-exclusion chromatography.
Since we observe a monomer/dimer equilibrium in nucleotide-
bound CtRoco, we next determined the dissociation constant of
this equilibrium under the different nucleotide conditions, using
sedimentation equilibrium AUC (SE-AUC) experiments (Supple-
mentary Fig. 6). Global analysis of the data using a single species
model indicated predominantly dimeric species for the
nucleotide-free (239 kDa) and the GDP-bound CtRoco (225
kDa), whereas a clear shift to the monomeric state for GppNHp-
bound CtRoco (177 kDa) is observed. Fitting the data for GDP-
and GppNHp-bound CtRoco using a monomer/dimer model
results in an approximate KD of 2 µM for GDP-bound CtRoco
and 30 µM for GppNHp-bound CtRoco (exclusively dimers are
found for nucleotide-free CtRoco) (Supplementary Fig. 6). Since
protein concentrations used for the SEC-SAXS, SEC-MALS, SV-
AUC and native MS experiments range between approximately
4.5 and 16 µM, these dissociation constants generally agree with
the predominantly dimeric form observed for CtRoco bound to
GDP and the shift to the monomeric form upon GppNHp
binding.
Finally, to further characterize the observed nucleotide-induced
changes in oligomerization we turned to negative stain electron
microscopy (EM). Thereto, CtRoco was applied on grids at a
concentration of 0.01 mgml−1 (0.08 µM) either in a nucleotide-
free state or pre-incubated with 1 mM GDP or GppNHp (Fig. 2f
and Supplementary Fig. 7). In the nucleotide-free state a rather
uniform population of “X-shaped” particles is observed, display-
ing seemingly a two-fold symmetry. We interpret these particles
as being the dimeric form of CtRoco. In contrast, in the presence
of GppNHp a uniform population of more elongated “worm-like”
particles is observed lacking the two-fold symmetry. We interpret
these particles to correspond to the monomeric form of CtRoco,
in agreement with the SAXS, SEC-MALS, native MS and AUC
experiments. For the GDP-bound state a mixture of particles
corresponding to dimers and monomers is observed.
In conclusion, we show that nucleotide binding also induces
monomerization of CtRoco in a concentration dependent
manner, with the GTP mimic GppNHp having a much stronger
effect than GDP.
Monomerization occurs on a relevant time scale. In order to be
relevant for the CtRoco-catalysed GTP hydrolysis reaction, the
observed monomerization should occur within a time frame that
is consistent with the time of a full GTP turnover cycle. The kcat
value for GTP hydrolysis of CtRoco and CtRoc-COR is 0.1 min−1
(Supplementary Fig. 8), meaning that it takes a protein molecule,
on average, approximately 10 min to travel through an entire
GTPase cycle under conditions of substrate saturation. For the
CtRoc-COR construct the rate of monomerization could be
measured using time-resolved FRET experiments making use of a
site-speciﬁc single cysteine mutant of this protein construct19. A
CtRoc-COR variant containing a single cysteine residue at posi-
tion 928 in the COR domain (S928C) was randomly labelled with
a Cy3/Cy5 FRET pair using maleimide-chemistry (Fig. 3a). Sta-
tistical incorporation should result in 50% incorporation with the
donor/acceptor pair. Subsequently, this nucleotide-free protein
was rapidly mixed in a stopped ﬂow apparatus with either buffer
or 50 µM GDP, GppNHp or GTP, and the decrease in FRET
signal linked to monomerization was followed (Fig. 3b). Com-
pared to the buffer control, a very small and slow decrease in
FRET signal is observed with GDP. In contrast, a fast decrease in
Fig. 2 Binding of a non-hydrolysable GTP analogue (GppNHp) to the Chlorobium tepidum Roco protein shifts the equilibrium toward the monomeric form. a
Scattering curves of CtRoco in the absence (black dots) or presence of nucleotides GDP (green dots) or GppNHp (red dots). b Superposition of the
crystallographic CtRoc-COR dimer model (Roc in red and COR in blue) onto the ab initio SAXS envelope, constructed starting from the scattering curve of
CtRoco in the absence of nucleotides. The envelope shows clear additional features corresponding to the N-terminal LRR domain and the C-terminal
domain, which are not present in the CtRoc-COR crystal structure. c Overview of the molecular masses obtained via SAXS (based on Porod volume/1.7),
SEC-MALS and SV-AUC for CtRoco in different nucleotide-bound states. The theoretical molecular mass of the monomer is given in between brackets.
(NF= nucleotide-free) d SEC-MALS data for CtRoco in the absence (black) or presence of nucleotides GDP (green) or GppNHp (red). e Native mass
spectra of CtRoco for the three different nucleotide states: nucleotide-free (NF), GDP-bound and GppNHp-bound. Peaks corresponding to dimeric and
monomeric species are labeled with two circles and one circle, respectively. f Top panels: negative-stain EM images (scale bar: 50 nm) of CtRoco in the
nucleotide-free state (black border), bound to GDP (green border) or bound to GppNHp (red border).Middle panels: 4x enlargements of boxed particles in top
panels (from left to right). Bottom panels: representative class averages (box size: 18.2 × 18.2 nm) for CtRoco in nucleotide-free state (black border), or bound
to GDP (green border) or GppNHp (red border). See also Supplementary Fig. 7 for an overview of all class averages
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FRET signal is observed upon mixing the protein with an excess
of either GppNHp or GTP. The decrease in signal and thus the
monomerization is signiﬁcantly faster upon mixing with GTP
compared to the GTP mimic GppNHp. While monomerization
reaches a steady state within less than 25 s with GTP, equilibrium
is only reached after more than 100 s with GppNHp. Such dif-
ferences between physiologically relevant nucleotides and
nucleotide analogues were described before26. In any case, the
observed time for monomerization is signiﬁcantly faster than the
GTP turnover time of about 10 min meaning that monomeriza-
tion happens on a catalytically relevant time scale.
Since cysteine-free full length CtRoco could not be obtained,
we turned to time-resolved EM measurements to estimate the
time frame of monomerization. Hereto, CtRoco was mixed with
an excess of GppNHp or GTP and samples were taken every two
minutes and immediately spotted on grids. In agreement with the
FRET experiments nearly full conversion of CtRoco from the “X-
shaped” dimers to the “worm-shaped” monomers is observed at
the 2 min time point (Fig. 3c), while a signiﬁcant amount of
monomerization has even taken place within the dead time (2
min) of the experiment. These experiments thus conﬁrm that
GTP-induced monomerization of CtRoco is fast and occurs
within the time frame of a catalytic cycle of GTP turnover.
CtRoco completes a monomer-dimer cycle during GTP turn-
over. Considering that GTP-induced formation of CtRoco/
CtRoc-COR monomers is fast compared to a complete GTP
turnover, we subsequently assessed whether the protein under-
goes a monomer-dimer cycle coupled to GTP turnover. We
therefore resorted to single turnover kinetic measurements (1 µM
protein +1 µM GTP), such that a complete single GTPase cycle
can be monitored.
Reversed-phase HPLC measurements show that, under the
experimental (non-saturating) conditions, it takes about 6000 s
for 1 µM CtRoc-COR to completely convert 1 µM GTP to GDP
(Fig. 4a). In turn, stopped-ﬂow measurements where 1 µM of
ﬂuorescent 2′-(or-3′)-O-(N-methylanthraniloyl)-GTP (mant-
GTP) is mixed with 1 µM of CtRoc-COR show a fast increase
in ﬂuorescence, coupled to mant-GTP binding and the associated
conformational changes, that occurs in a time frame of about 250
s (Fig. 4a). This fast binding phase is followed by a slow decrease
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in ﬂuorescence coupled to mant-GTP hydrolysis and return to
the initial conformation. In agreement with the data obtained
from the reversed-phase HPLC measurements, the total GTPase
cycle is ﬁnished within about 6000 s. Subsequently we followed
the monomerization of CtRoc-COR during single GTP-turnover
using our time-resolved FRET approach. 1 µM Cy3/Cy5-labelled
CtRoc-COR (S928C) was rapidly mixed with 1 µM GTP and the
FRET signal was followed over time (Fig. 4b). These traces show a
fast decrease in the FRET signal associated with monomerization,
followed by a slow increase in signal associated with dimerization.
This shows that the GTP-induced monomerization is reversible
and re-dimerization occurs upon GTP hydrolysis. The FRET
signal reaches a minimum at about 250 s. This time point of
maximal monomerization corresponds to the time point of
maximal GTP binding as determined from the ﬂuorescence
stopped-ﬂow experiments with mant-GTP. After this point the
FRET signal increases in a time frame that corresponds to GTP
hydrolysis and probably also GDP release (note that for
CtRocCOR KD(GDP)= 30.2 µM and KD(GppNHp)= 0.33 µM,
while a concentration of 1 µM is used here14).
Finally, we also assessed the oligomeric state of full length
CtRoco during single turnover GTP hydrolysis using time-
resolved negative stain EM measurements. Hereto, 1 µM of
CtRoco was mixed with 1 µM GTP and samples were taken at
different time points (0, 120, 240, 360, 1500, 3000 and 4500 s)
(Fig. 4c and Supplementary Fig. 9). Under these single turnover
conditions a large fraction of CtRoco molecules are converted
from a dimeric into a monomeric form after 240 s. This is
expected for a single turnover experiment where a mixture of
unbound, GTP-bound and post-hydrolysis GDP-bound CtRoco
molecules co-exist. After that time point the fraction of dimeric
protein is again increasing due to GTP hydrolysis, and after 4500
s, when all GTP is hydrolysed, a dimeric population reforms.
Thus, together these experiments clearly show that during the
GTPase cycle, CtRoco undergoes monomerization concomitant
with GTP binding and subsequent dimerization coupled to GTP
hydrolysis and GDP release.
An analogue of a PD mutation stabilizes the CtRoco dimer.
PD-associated mutations in LRRK2 are mainly located in the
kinase and Roc-COR domains. Mapping of the Roc-COR muta-
tions (LRRK2 I1371V/R1441C/Y1699C) onto the C. tepidum
Roc-COR crystal structure showed that the bacterial analogues of
these mutations (L487A/Y558A/Y804C) are all located in the
conserved interface between the Roc and COR sub-domains14.
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Fig. 4 The Chlorobium tepidum Roco protein undergoes a monomer-dimer cycle during GTP turnover. a Single turnover (mant-)GTP hydrolysis by CtRoc-
COR (S928C) followed by stopped ﬂow ﬂuorescence (black curve) and reversed-phase HPLC (red data points; each data point is the average (±s.d.) of 3
independent measurements). Rapid mixing of 1 µMmant-GTP and 1 µM unlabeled CtRoc-COR (S928C) in a stopped-ﬂow apparatus yields a rapid increase
in ﬂuorescence (time frame 1–250 s), followed by a slow decrease in a time frame of 6000 s. Following production of GDP from GTP in time via reversed-
phase HPLC shows that the increase in ﬂuorescence occurs prior to GDP production while all GTP is converted in the time scale of 6000 s. A split time axis
is used to highlight the two phases: fast ﬂuorescence increase associated with GTP binding and slow ﬂuorescence decrease concomitant with GTP
hydrolysis. b Stopped-ﬂow FRET signal obtained by mixing 1 µM of Cy3/Cy5- labeled CtRoc-COR (S928C) with 1 µM GTP. The traces show relatively fast
monomerization (ﬁrst phase from 1–250 s) followed by a slow return to the dimeric state after GTP hydrolysis. c Single GTP turnover of CtRoco followed by
time resolved EM. 1 µM CtRoco was mixed with 1 µM GTP and samples were taken at the indicated time points. Representative images for each time point
are shown (see also Supplementary Fig. 9) (scale bar: 50 nm)
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Since, in our hands, the Y558A and Y804C mutants show sig-
niﬁcant aggregation when analysed on size exclusion chromato-
graphy, we focused on the L487A mutant and analysed its effect
on the oligomeric state of the CtRoco and CtRoc-COR proteins
using SEC-MALS. Residue L487 corresponds to I1371 in LRRK2
and is located in the Roc domain, in the C-terminus of Switch 1,
at the interface of the Roc and COR domains. In their nucleotide-
free and GDP-bound states, both the CtRoco and CtRoc-COR
proteins that contain the L487A mutation are entirely dimeric, as
was also observed in the wild-type counterparts (Figs. 5a, b).
However, while in the GppNHp-bound form the monomer-
dimer equilibrium of the wild-type CtRoc-COR and CtRoco is
clearly shifted toward the monomeric form, the corresponding
proteins harboring the L487A mutation remain nearly completely
dimeric (Figs. 5a, b). Thus we ﬁnd that the PD-associated L487A
mutation stabilizes the dimeric form of the CtRoco protein. The
same behavior is observed when we compare the SAXS curves of
wild-type and L487A CtRoco in different nucleotide states
(Supplementary Fig. 10, 11). While the scattering curves, the
normalized Kratky plots27 and the pair distance distribution
function of the wild-type and L487A proteins nearly overlap in
the nucleotide-free and GDP states, the curves of both protein
variants clearly differ in the GppNHp-bound forms. This again
indicates that, while the L487A mutation does not cause any
large-scale conformational changes in the nucleotide-free and
GDP-bound dimers, it does stabilize the dimeric form of the
protein in the GppNHp-bound state.
Subsequently, we measured the GTPase activity of the wild-
type and L487A CtRoc-COR proteins under single-turnover
conditions and ﬁnd that the L487A mutation causes a 4-fold
decrease in the single-turnover rate constant (Fig. 5c). This is in
agreement with previous reports that show that the PD mutations
in the Roc-COR domain of LRRK2, as well as the counterparts in
CtRoco, decrease the GTPase activity10, 12, 28–30. We thus
speculate that monomerization of the Roco protein, which we
showed to be an integral part of the GTPase cycle, is hindered by
this PD-analogous mutation, thereby causing the pathological
decrease in GTPase activity. Hence, our data present a link
between the Roco monomer-dimer transition, the rate of GTP
turnover and disease.
Discussion
In the current study we show that the oligomerization of the
Chlorobium tepidum Roco protein depends on its nucleotide state.
In contrast to previous suggestions, we ﬁnd that the protein is
mainly monomeric when bound to GTP and dimeric in the
nucleotide-free state, while an intermediate situation is observed in
the GDP state. Moreover, we show that the CtRoco protein cycles
through the dimeric and monomeric conformations during a
round of GTP hydrolysis, meaning that these changes in oligo-
merization are an integral feature of the GTPase catalytic cycle.
Consequently, although many details still need to be resolved, a
mechanism as outlined in Fig. 6 can be proposed based on our
results. The reaction cycle starts with the rapid binding of a GTP
molecule to the Roc domains, followed by monomerization of the
protein as observed in SEC-MALS, SEC-SAXS, native MS, AUC
and EM (Figs. 1–3). Inter-domain and inter-subunit conforma-
tional changes leading to monomerization are likely triggered via
changes in conformation of the switch regions. The crystal struc-
ture of CtRoc-COR shows that especially switch II is ideally
positioned to transfer GTP-induced conformational changes from
the Roc domain to the COR domain within the same protomer as
well as to the adjacent COR domain14. The monomerization step is
followed by slow GTP hydrolysis concomitant with protein
dimerization (Fig. 4). Considering that single turnover GDP pro-
duction, as monitored via reversed-phase HPLC, occurs on the
same time scale as dimerization (Fig. 4), we assume GTP
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Fig. 5 Effect of a PD-analogous mutation on the CtRoco and CtRoc-COR monomer-dimer equilibrium. a SEC-MALS data for the CtRoc-COR L487A mutant
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hydrolysis to be the rate-limiting step in this process. Finally, GDP
is released, which may occur either after or concomitant with
protein dimerization since we ﬁnd CtRoco to be in equilibrium
between a monomeric and dimeric state in the presence of GDP.
Our observation that GTP hydrolysis occurs after mono-
merization contrasts with the current model that assumes that
Roco proteins, including LRRK2, function as GADs17, 18, 31. This
latter model is based largely on the crystal structure of the
nucleotide-free Roc-COR module of the C. tepidum Roco protein,
being the only available structure of a full Roc-COR tandem
domain14. This structure shows a Roc-COR dimer where the
dimer contacts are formed by the COR domain and with the GTP
binding sites of the Roc domains juxtaposed. This observation has
led to the hypothesis that GTP binding induces dimerization of
the Roc domains, with the reciprocal complementation of the
active sites ﬁnally leading to catalysis of GTP hydrolysis. We show
here, using the exact same protein, that GTP binding induces
monomerization and that GTP hydrolysis occurs after the
monomerization step. So far, it remains unclear whether Roco
monomerization is a strict requirement for GTP hydrolysis to
occur or whether GTP-induced monomerization and GTP
hydrolysis are two uncoupled phenomena. However, both EM
and SAXS indicate the occurrence of secondary inter-domain
conformational changes in the CtRoco monomers compared to
the dimers, with the protomers in the monomeric arrangement
being more elongated compared to the dimers (Fig. 2 and Sup-
plementary Fig. 4d). High resolution structural information of the
monomeric states could shed further light on the mechanism of
GTP hydrolysis. A second question that is triggered by our
ﬁndings concerns the role of dimerization within the reaction
cycle. A potential scenario would be that dimerization of the Roco
subunits leads to a decrease in the afﬁnity for GDP, thus
enhancing the rate of GDP release.
Since the presence of the Roc-COR module is highly conserved
throughout all Roco proteins, our current ﬁndings also throw new
light on LRRK2 functioning. However, apart from the Roc-COR
and LRR domain, LRRK2 also contains a kinase domain and a
number of domains typically involved in protein-protein inter-
actions, which potentially can have an additional inﬂuence on
oligomerization21, 32. Detailed and quantitative biophysical stu-
dies with LRRK2 to determine its oligomeric state remain highly
challenging since puriﬁcation yields are low, and puriﬁed LRRK2
is very heterogeneous and prone to degradation. However, it has
been shown that LRRK2 can form dimers via its Roc-COR
domain15, 20–22, while other studies indicate that LRRK2 can also
exist as a monomer18, 20, 23. Both observations can be reconciled
with our model. Interestingly, recent data suggest that LRRK2 can
exist as either a monomer or a dimer in the cell, where the
monomeric form prevails in the cytosol and the dimeric form is
more prominently present at the membrane21, 24, 25, 33. A higher
prevalence of a monomeric GTP-bound form under multiple
GTP turnover conditions such as present in the cytosol (GTP
concentrations in the cell are in a range of 1–1.6 mM34, 35)
corresponds to our in vitro observation in EM (Fig. 3). Following
the same argument, LRRK2 would exist in a more GDP-bound
form at the membrane. Apart from these considerations it is
likely that additional regulatory factors, such as phosphorylation
or interaction with other proteins, inﬂuence the monomer-dimer
equilibrium of LRRK2 in vivo36.
A number of point mutations in the Roc (R1441C/G/H) and
COR (Y1699C) domains of LRRK2 are directly linked to
PD1, 37, 38. These mutations have been related to a reduced
GTPase activity10, 12, 28–30, but so far no widely-accepted con-
sensus on the effect of PD mutations on homodimerization
exists22, 29, 33, 39. According to our model, whereby the CtRoco
protein needs to cycle through a monomeric and dimeric state,
stabilization of either could lead to a reduced GTPase activity. We
show that the L487A mutation in the Roc-COR interface (ana-
logous to I1371V in LRRK2) decreases the GTPase activity by
stabilizing the dimer interface (Fig. 5). Our results thus provide a
direct link between oligomerization, GTPase activity and disease
phenotype.
Because the kinase activity of LRRK2 is directly responsible for
neuronal toxicity9, 40, most efforts for therapeutic intervention are
focussed on the development of kinase-inhibitors41, 42. However,
long-term inhibition of LRRK2 by many of these inhibitors
increases the risk for morphological changes in lungs, similar to
what has been observed in LRRK2 knock-out models43–45. Our
ﬁndings now show that either increased dimerization or increased
monomerization could lead to changes in GTPase activity and
might form an appealing target for future drug development.
Methods
Protein expression and puriﬁcation. The DNA fragments coding for CtRoco (a.a.
1-1102) and CtRoc-COR (a.a. 412-946) were cloned in the pProEX plasmid with
N-terminal His-tags14. The plasmids were transformed in E. coli BL21 (DE3) cells.
Cells were grown at 37 °C in Terriﬁc Broth medium with 100 µg ml−1 ampicillin.
Once an optical density at 600 nm (OD600) of 0.7 was reached, 0.1 mM β-D-1-
thiogalactopyranoside (IPTG) was added and the temperature was dropped to
28 °C. After overnight incubation, the cells were harvested by centrifugation and
resuspended in buffer A (20 mM Hepes pH7.5, 150 mM NaCl, 5 mM MgCl2, 5%
glycerol, 1 mM DTT) with 50 µg ml−1 DNAse, 0.1 mg ml−1 AEBSF, 1 µg ml−1
leupeptin, and 200 µM GDP. Afterwards the cells were disrupted using a cell dis-
ruptor (Constant systems) and the soluble fraction was separated from the cell
debris via centrifugation. As a ﬁrst puriﬁcation step, an immobilized metal afﬁnity
chromatography (IMAC) step was performed. The supernatant containing the
soluble protein was loaded on Ni+2-NTA sepharose resin. The resin was extensively
washed with buffer A and subsequently the protein was eluted using buffer A
including 300 mM imidazole. The obtained protein was subsequently dialysed
against 20 mM Hepes pH 7.5, 150 mM NaCl, 5% glycerol, 1 mM DTT (buffer B).
Before the ﬁnal size exclusion chromatography puriﬁcation step, 1 mM EDTA was
added to the sample and the mixture was incubated for 1 h at 4 °C. Finally the
kcat = 0.1 min
–1
Monomerization
Hydrolysis
Dimerization
GDP release GTP binding
Fig. 6 Proposed monomer-dimer transitions during the GTP hydrolysis
cycle of CtRoco. In its nucleotide-free state the protein is dimeric. GTP
binding induces conformational changes that lead to fast monomerization.
In the monomeric state the protein hydrolyses GTP to GDP. Depending on
the protein concentration, protein dimerization could take place either after
or before release of GDP. After GDP is released, the cycle can restart. In the
cartoon of CtRoco, the LRR domain is coloured yellow, the COR domain blue,
the Roc domain dependent on the nucleotide state grey (nucleotide-free),
green (GDP-bound) or red (GTP-bound)
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sample was loaded on a Superdex S200 26/60 column (GE Healthcare) equilibrated
with buffer B. Fractions containing the protein were supplemented with 5 mM
MgCl2 and the nucleotide-load was determined using reversed-phase chromato-
graphy coupled to HPLC (see further).
SAXS and MALS experiments. SAXS experiments were performed on the BM29
beamline at the ESRF (Grenoble, France) and the SWING beamline at SOLEIL
(Paris, France), always with an inline HPLC set-up. 50 µl of an 8 mgml−1 protein
sample was injected on a Bio SEC-3 HPLC column (Agilent, 3 µm 300 Å) equili-
brated with 20 mM Hepes pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5% glycerol and 1
mM DTT (buffer A). For data collection in the presence of nucleotides, the
nucleotide-free proteins were pre-incubated with 1 mM of the nucleotide, and 200
µM (=molar excess) of the nucleotide was added to buffer A. Initial processing of
the data was done with DATASW46. PRIMUS was used for determination of the
radius of gyration (Rg) using the Guinier approximation47, and GNOM for the
calculation of the pair distance distribution function P(r)48. Modelling of missing
loops in the crystallographic dimer model of the CtRoc-COR was done using
ModLoop49 and the missing N- and C-terminus were added with CORAL50. The
ﬁnal dimer model was compared with the experimental data using CRYSOL51. Ab
initio envelopes were calculated using DAMMIN (average of 19 runs for CtRoc-
COR and 20 runs for CtRoco)52 followed by DAMAVER53. The ﬁnal model was
generated using one round of DAMMIN52, starting from the damstart model
generated by DAMAVER. Docking into the envelope was performed with Sup-
comb54. For docking into the CtRoco envelope, the position of the CtRoc-COR
dimer structure was manually adjusted. The molmap command in chimera was
used to convert the ab initio bead models into 20 Å density maps55. An overview of
the experimental and modelling parameters is provided in Supplementary
Tables 1–3.
For the SEC-MALS experiments, the samples were prepared and run in the
same way as for the SEC-SAXS experiments. 10 µl of an 8 mgml−1 protein sample
was injected on a Bio SEC-3 HPLC column (Agilent, 3 µm 300 Å). A Dawn Heleos
detector (using 9 angles) and Optilab T-rEX detector (Wyatt technology) were
attached to a HPLC (Shimadzu). The molar masses were calculated with the
ASTRA 5.3.4.20 software.
Native mass spectrometry. Protein samples were exchanged to a buffer con-
taining 150 mM ammonium acetate pH 7.5 using micro Bio-spin columns (Bio-gel
P6, Bio-rad). For measurements in the presence of nucleotide (GDP or GppNHp),
samples were pre-incubated with 500 µM nucleotide and 100 µM nucleotide was
added to the ammonium acetate buffer. Final protein concentrations ranged
between 12.5 and 16 µM. Samples were introduced into the vacuum of the mass
spectrometer using nanoelectrospray ionization with in-house-prepared, gold-
coated borosilicate glass capillaries with a spray voltage of +1.4 kV. Spectra were
recorded on a quadrupole TOF instrument (Q-TOF2, Waters) modiﬁed for
transmission of native, high-m/z protein assemblies, as described elsewhere56.
Critical voltages and pressures throughout the instrument were 120 and 25 V for
the sampling cone and collision voltage respectively, with pressures of 10 and 2E−2
mbar for the source and collision cell.
Analytical ultracentrifugation. Sedimentation velocity (SV-AUC) experiments on
CtRoco and CtRoc-COR were carried out at 20 °C in 20 mM HEPES pH 7.5, 150
mM NaCl, 5 mM MgCl2, 5% Glycerol and 100 µM of the respective nucleotides on
a Beckman Coulter ProteomLabTM XL-I analytical ultracentrifuge using the
absorbance at 280 nm. Samples were prepared at a concentration of 0.57 mgml−1
(4.5 µM) for CtRoco and 0.3 mgml−1 (4.6 µM) for CtRoc-COR. Standard double
sector centrepieces were used. The cells were scanned every minute and in total
200 scans were collected. The data was analysed using SEDFIT 15.01b57 with the
continuous c(s) distribution model. Solution density ρ, viscosity η and partial
speciﬁc volumes v were calculated using SEDNTERP58 (ρ= 1.02061 g l−1; η=
0.01197 kg s−1 m−1, v (CtRoco) = 0.7446, v (CtRoc-COR) = 0.7398). The c(s) ana-
lysis was carried out with an s range of 0 to 15 with a resolution of 200 and a
conﬁdence level of 0.68. In all cases, ﬁts were good, with root mean square
deviation (rmsd) values ranging from 0.005 to 0.012. Results were prepared for
publication using GUSSI 1.2.159.
Sedimentation equilibrium experiments (SE-AUC) on CtRoco were conducted
on the same instrument and under the same buffer conditions as SV-AUC
experiments using an Epon six-channel centrepiece and measurement of the
absorbance at 280 nm. Each sample was used at three different concentrations
(0.9 mgml−1/7.2 µM, 0.58 mgml−1/4.5 µM, and 0.35 mgml−1/2.7 µM). Samples
were centrifuged at 1164, 3407 and 9757 xg until sedimentation equilibrium was
reached. Three scans were taken at 280 nm at each point. The data was analysed
with a SEDPHAT60 software using either monomer-dimer or single-species model.
Figures were generated using GUSSI 1.2.1.59.
FRET and ﬂuorescence stopped ﬂow. The S928C mutant was generated in a
cysteine-free variant of CtRoc-COR using quick-change mutagenesis, as described
earlier19. 10 mg of completely reduced pure CtRoc-COR S928C protein was loaded
on a Superdex S200 16/60 column (GE Healthcare) equilibrated with a degassed
buffer composed of 20 mM Hepes pH 7, 150 mM NaCl, 5 mM MgCl2 and 5%
glycerol. Peak fractions were used to perform the labelling reaction with 8 µM
protein, 36 µM maleimide-Cy3 (Lumiprobe) and 36 µM maleimide-Cy5 (Lumip-
robe) in a total volume of 5 ml. After incubation at room temperature for 2 h, the
unreacted ﬂuorophores were separated from the labelled protein using size-
exclusion chromatography on a S200 16/60 column equilibrated with 20 mM
Hepes pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5% glycerol and 1 mM DTT. Labelling
stoichiometry was spectrophotometrically determined to be approximately 30% for
each ﬂuorophore. To determine the monomerization rate, 0.2 µM double labelled
protein was mixed with 100 µM nucleotide in a stopped ﬂow apparatus (Applied
Photophysics). To follow monomerization during single GTP-turnover, 2 µM Cy3/
Cy5-labelled CtRoc-COR was rapidly mixed with 2 µM GTP. The Cy3 ﬂuorophore
was excited at 540 nm and change in Cy5 emission was monitored using a cut-off
ﬁlter of 645 nm.
Mant-GTP binding and hydrolysis was followed in a stopped-ﬂow apparatus
(Applied Photophysics) by rapidly mixing 2 µM of protein with 2 µM of mant-
GTP. The mant-ﬂuorophore was excited at 360 nm and emission was followed
through a cut-off ﬁlter of 405 nm. All experiments were performed at 25 °C and at
least 3 time traces were averaged.
Negative stain electron microscopy. For negative stain electron microscopy, 2 µL
of a 0.01 mgml−1 protein sample was applied on a glow discharged carbon-coated
copper grid. After three short wash and blot steps with MilliQ water, the grids
were stained with a 1% uranyl formate solution. Grids were visualized with a JEOL
JEM-1400 electron microscope operating at 120 kV and equipped with a LaB6
cathode. Images were recorded on a CMOS TemCam-F416 camera (TVIPS,
Germany) at a nominal magniﬁcation of 80,000, a defocus of approximately 2 μm
and a corresponding pixel size of 1.42 Å.
For imaging the different nucleotide-bound states, 0.01 mgml−1 CtRoco protein
solutions were pre-incubated with 1 mM GDP or GppNHp. In the multiple
turnover experiment, 1 mM GTP/GppNHp was added to 0.01 mgml−1 CtRoco
protein. For the single turnover experiment, where turnover of 1 µM GTP by
1 µM CtRoco was followed, samples were diluted to 0.01 mgml−1 right before
spotting. In both experiments samples were taken at the following time points: 0, 2,
4, 6, 25, 50 and 75 min. The time-resolved EM experiments were performed
at 25 °C. For the calculation of class averages, 11,571 particles for the nucleotide-
free state, 9620 particles for the GDP-bound state and 11,164 for the GppNHp-
bound state were selected using e2boxer61. Further classiﬁcation was done with
SPARX62.
GTP hydrolysis assays. GTP hydrolysis experiments were performed at 25 °C in
20 mM Hepes pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5% glycerol and 1 mM DTT.
The GTP-GDP mixture was separated using a C18-reversed phase column
(Phenomenex, Jupiter 5 µm C18 300 Å) coupled to a HPLC system (Waters), using
100 mM KH2PO4 pH 6.4, 10 mM tetra butyl-ammonium-bromide and 7.5%
acetonitrile as a mobile phase. Nucleotide elution was followed using absorbance
at 254 nm. The area of GDP was converted to concentration using a standard
curve.
Time points for the single turnover experiments with 1 µM protein and
1 µM GTP were 0, 2, 6, 13, 20, 30, 40, 60, 80 and 100 min. For the multiple
turnover steady state experiments 0.2 µM protein was incubated with different
concentrations of GTP (25, 50, 100, 175, 250 µM) and samples were taken
after 0, 30, 60, 90 and 120 min. Kinetic parameters were determined by ﬁtting the
data to a single exponential (single turnover) or the Michaelis-Menten equation
(multiple turnover) using GraphPad Prism 6. All experiments were done in
triplicate.
Data availability. All data supporting the ﬁndings of this study are available from
the corresponding author upon reasonable request. All SAXS data and derived
models were deposited in the SASDB (CtRocCOR NF: SASDCB2, CtRocCOR
GDP: SASDCC2, CtRocCOR GppNHp: SASDCD2, CtRoco NF: SASDC82, CtRoco
GDP: SASDCA2, CtRoco GppNHp: SASDC92, CtRoco L487A NF: SASDCG2,
CtRoco L487A GDP: SASDCE2, CtRoco L487A GppNHp: SASDCF2).
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